ReviewCurrent opinion in lipidology2014
Apolipoprotein A-I mimetics.
Review in Current opinion in lipidology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 46 citations in OpenAlex.
- From lipid dysbalance to cardiorenal decompensation: apoB/ApoA1 ratio is associated with acute cardiorenal injury in CAD patients.Frontiers in cardiovascular medicine · 2026Article
- Review
- ERα promotes transcription of tumor suppressor geneJournal of Zhejiang University. Science. B · 2021Article
- HDL and persistent inflammation immunosuppression and catabolism syndrome.Current opinion in lipidology · 2021Review
- Apolipoprotein mimetics in cancer.Seminars in cancer biology · 2021Review
- Revealing the Role of High-Density Lipoprotein in Colorectal Cancer.International journal of molecular sciences · 2021Review
- Review
- Oral 15-Hydroxyeicosatetraenoic Acid Induces Pulmonary Hypertension in Mice by Triggering T Cell-Dependent Endothelial Cell Apoptosis.Hypertension (Dallas, Tex. : 1979) · 2020Article
- Reconfiguring Nature's Cholesterol Accepting Lipoproteins as Nanoparticle Platforms for Transport and Delivery of Therapeutic and Imaging Agents.Nanomaterials (Basel, Switzerland) · 2020Review
- Lipoprotein-based drug delivery.Advanced drug delivery reviews · 2020Review
- Apolipoproteins and cancer.Cancer medicine · 2019Review
- Artificial High Density Lipoprotein Nanoparticles in Cardiovascular Research.Molecules (Basel, Switzerland) · 2019Review
- Review
- AIBP and APOA-I synergistically inhibit intestinal tumor growth and metastasis by promoting cholesterol efflux.Journal of translational medicine · 2019Article
- Apolipoprotein A-1 mimetic peptide 4F promotes endothelial repairing and compromises reendothelialization impaired by oxidized HDL through SR-B1.Redox biology · 2018Article
- Soft Drusen in Age-Related Macular Degeneration: Biology and Targeting Via the Oil Spill Strategies.Investigative ophthalmology & visual science · 2018Review
- Cholesterol levels and long-term rates of community-acquired sepsis.Critical care (London, England) · 2016Article
- ApoA-I mimetic administration, but not increased apoA-I-containing HDL, inhibits tumour growth in a mouse model of inherited breast cancer.Scientific reports · 2016Article
- The A's Have It: Developing Apolipoprotein A-I Mimetic Peptides Into a Novel Treatment for Asthma.Chest · 2016Review
- Transintestinal transport of the anti-inflammatory drug 4F and the modulation of transintestinal cholesterol efflux.Journal of lipid research · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
purpose of reviewTo summarize recent publications in the field of apolipoprotein mimetics. RECENT
findingsApolipoprotein mimetic peptides continue to show efficacy in a number of animal models of disease and demonstrate properties that make them attractive as potential therapeutic agents. A number of new apolipoprotein mimetics have been described recently. A major site of action of apolipoprotein mimetic peptides was found to be in the small intestine in which they decrease the levels of proinflammatory bioactive lipids. A major problem related to the use of apolipoprotein mimetic peptides is their cost, particularly those that need to be generated by solid phase synthesis with chemical addition of end-blocking groups. Novel approaches to apolipoprotein mimetic therapy have emerged recently that show promise in overcoming these barriers. SUMMARY: Despite the recent failure of therapies designed to raise HDL-cholesterol in humans, an approach to therapy using mimetics of HDL and its components continues to show promise.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.